title: Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
abstract: Hyperprolactinemia is a frequent consequence of treatment with some antipsychotic agents. Although prolactin secretion varies over the course of a day and during psychological circumstances, there is little information in the literature regarding the time dependence of the prolactin response to antipsychotics. We evaluated prolactin levels in schizophrenic patients receiving risperidone (3 mg twice daily), olanzapine (10 mg twice daily), or perospirone (16 mg twice daily) for at least 4 weeks. The subjects were compared to matched healthy controls. Plasma sample collection for quantification of drug and prolactin levels was conducted before and 2, 4, 6, 8, and 12 h after the morning dosing. Prolactin concentrations before dosing during risperidone treatment were significantly higher than during treatment with olanzapine and perospirone in females. The daily fluctuation of prolactin concentration after perospirone treatment was larger than that observed after risperidone and olanzapine treatments. Areas under the plasma concentration-time curves was greatest in subjects treated with risperidone, followed by perospirone and finally by olanzapine. These findings suggest that daily fluctuations in prolactin concentration after perospirone treatment are larger than following treatment with risperidone and olanzapine. The plasma concentration of prolactin during perospirone treatment therefore depends on the time of sampling.
authors.affiliation: Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan. yasufuru@cc.hirosaki-u.ac.jp
authors.forename: Norio
authors.initials: N
authors.lastname: Yasui-Furukori
authors.forename: Hanako
authors.initials: H
authors.lastname: Furukori
authors.forename: Norio
authors.initials: N
authors.lastname: Sugawara
authors.forename: Shoko
authors.initials: S
authors.lastname: Tsuchimine
authors.forename: Akira
authors.initials: A
authors.lastname: Fujii
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Inoue
authors.forename: Sunao
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced; D054833:Isoindoles / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011388:Prolactin / Q000097:blood*; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D054833:Isoindoles; D013844:Thiazoles; D001569:Benzodiazepines; D011388:Prolactin; D018967:Risperidone; C065533:perospirone; D000077152:Olanzapine